

FORM G

INVITATION FOR EXPRESSION OF INTEREST FOR

MALIHA REALTORS PRIVATE LIMITED OPERATING IN REAL ESTATE AT NCR

(Under sub-regulation (1) of regulation 36A of the Insolvency and Bankruptcy Board of India (Insolvency Resolution Process for Corporate Persons) Regulations, 2016)

SL.	RELEVANT PARTICULARS	
1.	Name of the corporate debtor along with PAN & CIN/ LLP No.	MALIHA REALTORS PRIVATE LIMITED CIN: U70109DL2008PTC178745 PAN: AAFCM5934K
2.	Address of the registered office	Registered Office: 676, Ground Floor Chitla Gate, Chawari Bazar, North Delhi, Delhi, India, 110006
3.	URL of website	https://cirpmaliha.in/
4.	Details Of Place Where Majority Of Fixed Assets Are Located	The company is engaged in the Real Estate Business and the project is located at: Khasra No.61,70,71,72,74 Elaichipur Village, Soniya Vihar Pushta Road, Loni, Ghaziabad-201102 (Near Tronica City).
5.	Installed capacity of main products/services	The flats/units are partially constructed in the project, the proposed flats as per available information are 220 units & convenient shops are 5 shops.
6.	Quantity and value of main products/services sold in last financial year	The company is engaged in the business of Real Estate and currently has only one project namely " TAJ HEIGHTS " which is partially constructed and the construction seems to have stopped around Four years back.
7.	Number of employees/ workmen	Nil
8.	Further details including last available financial statements (with schedules) of two years, lists of creditors are available at URL:	Can be sought by sending a request to the resolution professional at: cirp.maliha@gmail.com
9.	Eligibility for resolution applicants under section 25(2)(h) of the Code is available at URL:	Can be sought by sending a request to the resolution professional at: cirp.maliha@gmail.com
10.	Last date for receipt of expression of	25.08.2025

	interest	
11.	Date of issue of provisional list of prospective resolution applicants	04.09.2025
12.	Last date for submission of objections to provisional list	09.09.2025
13.	Date of issue of final list of prospective resolution applicants	19.09.2025
14.	Date of issue of information memorandum, evaluation matrix and request for resolution plans to prospective resolution applicants	24.09.2025
15.	Last date for submission of resolution plans	24.10.2025
16.	Process email id to submit Expression of Interest	cirp.maliha@gmail.com
17.	Details of the Corporate Debtor's registration status as MSME.	The Corporate Debtor is registered with Ministry of Micro, Small and Medium Enterprise (Udyam Registration No. UDYAM-UP-29-0146634)

SD/-
 Anurag Nirbhaya
 Resolution Professional
For Maliha Realtors Private Limited
 Regn. No.: **IBBI/IPA-001/IP-P00870/2017-2018/11468**
 Regd. Address: **204, Sagar Plaza, Plot No. 19,
 District Centre, Laxmi Nagar, New Delhi-110092**

Date: 05-08-2025
 Place: New Delhi

ASBA has to be availed by all the investors. UPI may be availed by (i) Individual Investors Portion. (ii) Non-Institutional Investors with an application size of up to Rs. 5,00,000 in the Non-Institutional Portion. For details on the ASBA and UPI process, please refer to the details given in ASBA form and abridged prospectus and also please refer to the section "Issue Procedure" on page no. 297 of the Prospectus. The process is also available on the website of Association of Investment Bankers of India ("AIBI") and Stock Exchanges and in the General Information Document. ASBA bid-cum-application forms can be downloaded from the websites of Stock Exchange and can be obtained from the list of banks that is displayed on the website of SEBI at <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&htmlid=35> and <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&htmlid=43>, respectively as updated from time to time. For the list of UPI apps and banks live on IPO, please refer to the link: www.sebi.gov.in. UPI mechanism may apply through the SCSBs and mobile applications whose names appear on the website of SEBI, as updated from time to time. ICICI Bank Limited has been appointed as Sponsor Banks for the issue, in accordance with the requirements of the SEBI Circular dated November 1, 2018 as amended. For Issue related queries, please contact the BRLMs on their respective email IDs as mentioned below. For UPI related queries, Investors can contact NPCI at the toll-free number: 18001201740 and mail ID: ipd.upi@nplc.org.in.

In case of any revisions in the Price, the Bid/ Issue Period will be extended by at least three additional Working Days after such revision of the Price, subject to the Bid/ Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company may, for reasons to be recorded in writing, extend the Bid/ Issue Period for a minimum one Working Day, subject to the Bid/ Issue Period not exceeding 10 Working Days. Any revision in the Price and the revised Bid/ Issue Period, if applicable, will be widely disseminated by notification to the Stock Exchange, by issuing a press release, and also by indicating the change on the website of the Book Running Lead Managers and the terminals of the other members of the Syndicate and by intimation to SCSBs, the Sponsor Bank, Registered Brokers, Collecting Depository Participants and Registrar and Share Transfer Agents.

The Offer is being made through the Fixed Price Issue, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (the "SCR") read with Regulation 252 of SEBI ICDR Regulations, 2018, The Offer is being made for at least 25% of the post-offer paid-up Equity Share capital of our Company. The Offer is being made under Regulation 229(2) of Chapter IX of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 via fixed issue process All Bidders for details, see "Issue Procedure" beginning on page no. 297 of the Prospectus.

Bidders/ Applicants should note that on the basis of PAN, DP ID and Client ID as provided in the Bid cum Application Form, the Bidders/Applicants may be deemed to have authorized the Depositories to provide to the Offer, any requested Demographic Details of the Bidders/Applicants as available on the records of the Depositories. These Demographic Details may be used, among other things, for or unlocking of ASBA Account or for other correspondence(s) related to an Issue. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Applicants' sole risk. Bidders/Applicants should ensure that PAN, DP ID and the Client ID are correctly filled in the Bid cum Application Form. The PAN, DP ID and Client ID provided in the Bid cum Application Form should match with the PAN, DP ID and Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidders/Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active. Investors must ensure that their PAN is linked with Aadhar and are in compliance with CBDT Notification dated February 13, 2020 and press release dated June 25, 2021.

CONTENTS OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AS REGARDS ITS OBJECTS: For information on the main objects and other objects of our Company, see "Our History and Certain Corporate Matters" on page no. 179 of the Prospectus and Clause III of the Memorandum of Association of our Company. The Memorandum of Association of our Company is a material document for inspection in relation to the Issue. For further details, see the section "Material Contracts and Documents for Inspection" on page no. 339 of the Prospectus.

LIABILITY OF MEMBERS AS PER MOA: Limited by shares.

AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE: As on the date of Prospectus, the Authorized share Capital of the Company is Rs. 15,00,00,000/- (Rupees Fifteen Crores Only) divided into 1,50,00,000 (One Crore and Fifty Lakhs Only) Equity Shares of face value of Rs.10/- each. The issued, subscribed and paid-up share capital of the Company before the issue Rs. 10,46,55,460.00/- (Rs. Ten Crores Forty-Six Lakhs and Fifty-Five Thousand Four Hundred and Sixty Only) divided into 1,04,65,546 (One Crore Four Lakhs Sixty-Five Thousand Five Hundred and Forty Six Only). For details of the Capital Structure, see "Capital Structure" on the page no. 73 of the Prospectus.

NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM: Given below are the names of the signatories of the Memorandum of Association of the Company and the number of Equity Shares subscribed for them by the time of signing of the Memorandum of Association of our Company, Ms. Nishakumari Vicky Agrawal - 100 equity shares, Mr. Dabhi Dharmishaben V- 100 equity shares, Mr. Vishnu Kumar- 100 equity shares, Mr. Vicky Mahadev Agrawal- 100 equity shares, Ms. Prajapati Hetaliben Gordhral - 9,400 equity shares and Mr. Gordhral Prajapati - 100 equity shares of Rs.10/- each. Details of the main objects of the Company as contained in the Memorandum of Association, see "History and Certain Corporate Matters" on page no. 179 of the Prospectus. For details of the share capital and capital structure of the Company see "History and Certain Corporate Matters" on page no. 179 of the Prospectus.

LISTING: The Equity Shares offered through the Prospectus are proposed to be listed on the SME platform of NSE ("NSE Emerge"). Our Company has received an "In-principle" approval from the NSE for the listing of the Equity Shares pursuant to letter dated May 07, 2025. For the purposes of the Offer, the Designated Stock Exchange shall be NSE. A signed copy of the Prospectus has been submitted for registration to the ROC on August 04, 2025 and Prospectus shall be filed with the ROC in accordance with Section 26(4) of the Companies Act, 2013.

DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA ("SEBI"): Since the Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018. The Prospectus has been filed with SEBI. In terms of the SEBI Regulations, the SEBI shall not issue any observation on the Offer Document. Hence there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire Disclaimer Clause of SEBI beginning on page no. 276 of the Prospectus.

DISCLAIMER CLAUSE OF NSE ("NSE EMERGE") (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Offer Document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to the Offer Document for the full text of the "Disclaimer" Clause of NSE.

GENERAL RISK: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of the Issuer and this Issue, including the risks involved. The Equity Shares have

not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of the Prospectus. Specific attention of the investors is invited to "Risk Factors" on page no. 30 of the Prospectus.

TRACK RECORD OF LEAD MANAGER: The LM associated with the Issue has handled 11 Public Issues in the past three years out of which 3 issue was closed below the Issue/ Offer Price on listing date

Name of LM	Total Issue in last 3 years	Issue closed below IPO Price on listing date
Mainboard	SME	
Fast Track Finsec Private Limited	0	11
		3
LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 Fasttrack Finsec Category-I Merchant Banker	 CAMEO	Ms. Sashi Kala Bhutra, Company Secretary & Compliance Officer Address: - 05, S. No-245/B, Plot-19, M-56, Free Way Trade Center, Nr. A-One Hotel, N.H.-8, Narol Gam, Narol, Ahmedabad City, Daskroi, Gujarat, India, 382405 Tel.: +91 87808 46963 E-mail: Info@medistephc.com Website: www.medistephc.com

Investors can contact our Company Secretary and Compliance Officer, the Lead Manager or the Registrar to the Issue, in case of any pre-issue or post-issue related problems, such as non-receipt of letters of allotment, non-credit of allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders and non-receipt of funds by electronic mode etc.

AVAILABILITY OF PROSPECTUS: Investors are advised to refer to the Prospectus and the Risk Factors contained therein before applying in the Issue. Full copy of the Prospectus is available on the website of the SEBI at www.sebi.gov.in, website of company at www.medistephc.com, the website of the Lead Manager to the Issue at www.ftfinsec.com, and websites of stock exchange at www.nseindia.com.

AVAILABILITY OF THE ABRIDGED PROSPECTUS: A copy of the abridged prospectus shall be available on the website of the Company, LM and NSE at www.medistephc.com, www.ftfinsec.com and www.nseindia.com.

AVAILABILITY OF BID-CUM-APPLICATION FORMS: Bid-Cum-Application forms can be obtained from the Registered Office of the Company: Medisteph Healthcare Limited (Telephone: 91 87808 46963) **Lead Manager:** Fast Track Finsec Private Limited (Telephone: +91-11-43029809), Bid-cum-application Forms will also be available on the website of NSE (www.nseindia.com) and the designated branches of SCSBs, the list of which is available at websites of the Stock Exchange and SEBI.

SYNDICATE MEMBER: N.A.

BANKER TO THE ISSUE/ ESCROW COLLECTION BANK/ REFUND BANK/ PUBLIC ISSUE ACCOUNT BANK/ SPONSOR BANK: ICICI Bank Limited.

SPONSOR BANKS: ICICI Bank Limited

UPI: Bidders can also Bid through UPI Mechanism.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Prospectus.

For & On Behalf of the Board of Directors

Medisteph Healthcare Limited

Sd/-

Sashi Kala Bhutra

Company Secretary and Compliance Officer

Place: Ahmedabad
Date: August 04, 2025
Disclaimer: - Medisteph Healthcare Limited proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares the Prospectus dated August 04, 2025 has been filed with the Registrar of Companies, Ahmedabad and thereafter with SEBI and the Stock Exchanges. The Prospectus is available on the website of the SEBI at www.sebi.gov.in, website of NSE www.nseindia.com and is available on the websites of the LM at www.ftfinsec.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the section titled "Risk Factors" beginning on page no. 30 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in 'offshore transactions' in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

Place: Ahmedabad
Date: August 04, 2025
Disclaimer: - Medisteph Healthcare Limited proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares the Prospectus dated August 04, 2025 has been filed with the Registrar of Companies, Ahmedabad and thereafter with SEBI and the Stock Exchanges. The Prospectus is available on the website of the SEBI at www.sebi.gov.in, website of NSE www.nseindia.com and is available on the websites of the LM at www.ftfinsec.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the section titled "Risk Factors" beginning on page no. 30 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in 'offshore transactions' in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

SYNDICATE MEMBER: N.A.

BANKER TO THE ISSUE/ ESCROW COLLECTION BANK/ REFUND BANK/ PUBLIC ISSUE ACCOUNT BANK/ SPONSOR BANK: ICICI Bank Limited.

SPONSOR BANKS: ICICI Bank Limited

UPI: Bidders can also Bid through UPI Mechanism.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Prospectus.

For & On Behalf of the Board of Directors

Medisteph Healthcare Limited

Sd/-

Sashi Kala Bhutra

Company Secretary and Compliance Officer

Place: Ahmedabad
Date: August 04, 2025
Disclaimer: - Medisteph Healthcare Limited proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares the Prospectus dated August 04, 2025 has been filed with the Registrar of Companies, Ahmedabad and thereafter with SEBI and the Stock Exchanges. The Prospectus is available on the website of the SEBI at www.sebi.gov.in, website of NSE www.nseindia.com and is available on the websites of the LM at www.ftfinsec.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the section titled "Risk Factors" beginning on page no. 30 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in 'offshore transactions' in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

SYNDICATE MEMBER: N.A.

BANKER TO THE ISSUE/ ESCROW COLLECTION BANK/ REFUND BANK/ PUBLIC ISSUE ACCOUNT BANK/ SPONSOR BANK: ICICI Bank Limited.

SPONSOR BANKS: ICICI Bank Limited

UPI: Bidders can also Bid through UPI Mechanism.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Prospectus.

For & On Behalf of the Board of Directors

Medisteph Healthcare Limited

Sd/-

Sashi Kala Bhutra

Company Secretary and Compliance Officer

Place: Ahmedabad
Date: August 04, 2025
Disclaimer: - Medisteph Healthcare Limited proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares the Prospectus dated August 04, 2025 has been filed with the Registrar of Companies, Ahmedabad and thereafter with SEBI and the Stock Exchanges. The Prospectus is available on the website of the SEBI at www.sebi.gov.in, website of NSE www.nseindia.com and is available on the websites of the LM at www.ftfinsec.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the section titled "Risk Factors" beginning on page no. 30 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in 'offshore transactions' in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

SYNDICATE MEMBER: N.A.

BANKER TO THE ISSUE/ ESCROW COLLECTION BANK/ REFUND BANK/ PUBLIC ISSUE ACCOUNT BANK/ SPONSOR BANK: ICICI Bank Limited.

SPONSOR BANKS: ICICI Bank Limited

UPI: Bidders can also Bid through U